U.S. FDA Approves ZEVASKYN, the First and Only FDA-approved Product for Recessive Dystrophic Epidermolysis Bullosa April 29, 2025
Oncodermatology News: Topical BRAF Inhibitor Gel May Relieve Anti-EGFR Therapy-related Skin Rash April 28, 2025